ExodusPoint Capital Management LP lifted its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO – Free Report) by 483.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,020,401 shares of the company’s stock after buying an additional 845,648 shares during the quarter. ExodusPoint Capital Management LP owned 0.78% of Organogenesis worth $2,173,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Baird Financial Group Inc. purchased a new stake in shares of Organogenesis during the 4th quarter valued at about $29,000. Point72 Hong Kong Ltd raised its holdings in shares of Organogenesis by 245.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after buying an additional 4,275 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Organogenesis during the 4th quarter valued at about $30,000. Mackenzie Financial Corp purchased a new stake in shares of Organogenesis during the 1st quarter valued at about $36,000. Finally, Jane Street Group LLC acquired a new stake in Organogenesis during the 4th quarter valued at approximately $37,000. 39.48% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on ORGO. Morgan Stanley lowered their price objective on Organogenesis from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 11th. BTIG Research lowered their price objective on Organogenesis from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, August 10th.
Organogenesis Price Performance
Shares of ORGO opened at $2.80 on Friday. The firm has a market cap of $367.67 million, a price-to-earnings ratio of 35.00 and a beta of 1.45. The stock has a 50 day moving average of $3.43 and a 200-day moving average of $2.95. The company has a current ratio of 2.95, a quick ratio of 2.60 and a debt-to-equity ratio of 0.24. Organogenesis Holdings Inc. has a 52 week low of $1.79 and a 52 week high of $4.50.
Organogenesis (NASDAQ:ORGO – Get Free Report) last issued its earnings results on Wednesday, August 9th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $117.32 million during the quarter, compared to analyst estimates of $115.25 million. Organogenesis had a return on equity of 5.65% and a net margin of 2.20%. As a group, analysts forecast that Organogenesis Holdings Inc. will post -0.01 EPS for the current year.
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.
- Five stocks we like better than Organogenesis
- How to Invest in Blue Chip Stocks
- 3 Takeaways from the August Inflation Report
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- High Flyers: 3 Natural Gas Stocks for March 2022
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.